Assessment of aspirin response in patients undergoing neuroendovascular treatments: A comparison of five platelet function tests across two platforms
Aspirin is widely used for periprocedural antiplatelet therapy in neuroendovascular procedures; however, variability in patient response poses clinical challenges. This study aimed to assess five platelet function tests on two different platforms: light transmission aggregometry (LTA) using the CN-6000 device and the VerifyNow system, which were utilized to assess patients undergoing neuroendovascular procedures. A total of 124 patients who underwent elective neuroendovascular procedures and received perioperative aspirin-based antiplatelet therapy between September 2020 and December 2023 were retrospectively reviewed. Platelet function was assessed at three time points: before surgery, 1–3 days after surgery, and 1 month following the procedure. The assessments included maximum aggregation (MA) induced by 1 mM arachidonic acid (AA), 10 μM ADP, and 1 μg/mL collagen, as well as collagen-induced platelet aggregation level (CPAL) and aspirin reaction units (ARU). Significant perioperative changes were observed only with 1 mM AA MA, which increased immediately after surgery (p < 0.001) and decreased at 1 month (p = 0.013), while other tests showed no significant differences. Correlation analysis revealed the strongest association between 1 mM AA MA and 1 μg/mL collagen MA (r = 0.65), followed by CPAL (r = 0.62). ARU correlated modestly with LTA-based measures (r ≤ 0.34). Receiver operating characteristic analysis identified CPAL >6.0 and collagen MA > 43.2% as equivalent to AA MA > 20%. In this cohort, perioperative changes were detected by 1 mM AA MA but not by the other platelet function tests, and correlations between VerifyNow ARU and LTA-based measurements were modest. However, the clinical significance of these differences remains to be established. Automated LTA using CN-6000 may offer a practical option for aspirin monitoring in patients undergoing neuroendovascular procedures. Further prospective studies are warranted to validate its clinical utility.
Authors
- Yukiko Enomoto (ORCID: https://orcid.org/0000-0003-0019-7029)
- Tasuku Sakayori (ORCID: https://orcid.org/0000-0001-7872-1199)
- Keisuke Kitano (ORCID: https://orcid.org/0000-0002-3350-0488)
- Kenji Shoda (ORCID: https://orcid.org/0000-0003-1021-7388)
- Daisuke Mizutani
- Ryosuke Kikuchi (ORCID: https://orcid.org/0000-0002-9403-4302)
- Ayumu Kanbe (ORCID: https://orcid.org/0000-0003-2257-5676)
- Aki Oka
- Yoshihiko Ueno
- Miyu Kitagami
- Ryosuke Nakanishi
Institutions
- Gifu University Hospital (JP)
- Tokushima Municipal Hospital (JP)
- Gifu University (JP)
- Sysmex (Japan) (JP)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1371/journal.pone.0363376
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00